{"id":"NCT04211389","sponsor":"Arcutis Biotherapeutics, Inc.","briefTitle":"Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","officialTitle":"A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-17","primaryCompletion":"2020-11-23","completion":"2020-11-23","firstPosted":"2019-12-26","resultsPosted":"2022-10-18","lastUpdate":"2022-12-07"},"enrollment":442,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"ARQ-151 0.3% cream","otherNames":[]},{"type":"DRUG","name":"ARQ-151 vehicle cream","otherNames":[]}],"arms":[{"label":"ARQ-151 cream 0.3%","type":"ACTIVE_COMPARATOR"},{"label":"ARQ-151 cream vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day for 56 days by subjects with chronic plaque psoriasis","primaryOutcome":{"measure":"Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale","timeFrame":"Week 8","effectByArm":[{"arm":"Roflumilast Cream 0.3%","deltaMin":99,"sd":null},{"arm":"Vehicle Cream","deltaMin":9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":1},"locations":{"siteCount":39,"countries":["United States","Canada"]},"refs":{"pmids":["36422852","36125472"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":290},"commonTop":[]}}